Biopharma Innovations Summit Day 1

Join us for an exclusive two-day event where Agilent will showcase cutting-edge biopharma solutions.

The first day of the event we will explore Agilent’s comprehensive portfolio for the spectrum of applications from drug discovery to quality control. Learn more about our cell analysis and genomics expertise and the tools we provide to drive IVT mRNA development, protein therapeutics and cell and gene therapies

The second day will focus on advanced analytical solutions, including HRMS for tRNA sequencing and LC/MS for DNA/RNA analysis. Learn how to scale up oligonucleotide purification with Agilent biocolumns, which enhance the efficiency and accuracy of your processes.

By attending this event you will:

• Gain insights from Agilent to optimize biotherapeutic workflows, including rigorous quality testing in cGMP environments and handling nucleic acid, vaccines, mAB and protein samples.

• Understand how metabolic analyses can impact CAR cell function and behavior, using cytolytic cell killing assays on the xCELLigence system to develop cell therapy processes and confirm product potency.

• Learn about new techniques in high-resolution LC/MS for analyzing tRNA modifications.

• Discover software tools available for high-resolution MS systems in both research and QA/QC labs.

• Compare analytical and semipreparative LC purification methods for synthetic oligonucleotides, gaining competitive insights into purification strategies.

Talk 1: Agilent Tools and Technologies to Drive Advancements in Biopharmaceutical Drug Development

• Presented by Dr. Hervé Chaulet, Molecular and Biological Research Market Specialist, Agilent Technologies

Discovering, developing, and manufacturing biopharmaceuticals requires you to stay abreast of advances in knowledge and improvements in technology while constantly navigating a maze of business and scientific challenges. Agilent can be a trusted partner providing expertise and end-to-end workflows including systems, software, consumables, and services for the spectrum of applications from drug discovery to quality control. Learn more about our cell analysis and genomics expertise and the tools we provide to drive IVT mRNA development, protein therapeutics, and cell and gene therapies.

Talk 2: Quality Control In IVT mRNA Therapeutics and Vaccine Development Workflow Using The Agilent Fragment Analyzer System

• Presented by Dr. Leslie Friedmann, Product Manager, Agilent Technologies

Reliable and robust analysis is essential throughout in vitro transcription (IVT) mRNA workflows, providing important quality information to help minimize risk and aid in the production of a consistent product. The Agilent Fragment Analyzer systems can be used for several QC steps at different checkpoints in mRNA vaccine development, providing accurate and precise sizing and integrity analysis. These QC steps are to determine the quality and size of the linearized plasmid, the size and purity of the IVT mRNA, length of the poly(A) tail, and purity of the final mRNA vaccine product.

Talk 3: Analysis of NIST mAb Reference Material by Parallel SDS-Capillary Electrophoresis

• Presented by Dr. Kyle Luttgeharm, Product Manager, Agilent Technologies

Monoclonal antibody drug products are complex biomolecules that must be tested for critical quality attributes (CQAs) such as monomeric purity and percent glycosylation. Capillary gel electrophoresis methods have been adopted as the standard method for size heterogeneity characterization, however legacy capillary electrophoresis (CE) methods involve complicated workflows or are cost prohibitive. To address these problems with legacy methods, Agilent has developed a 12-channel, parallel capillary electrophoresis-SDS (CE-SDS) instrument and reagents. The system uses a high-resolution sieving gel, allowing for resolution of mAb species including the non-glycosylated heavy chain and light chain. To demonstrate the capabilities of the ProteoAnalyzer, the NIST mAb was characterized under both reduced and non-reduced conditions and compared to the NIST data sheet.

Talk 4: Advanced Analytics for Cell Therapy Research, Process Development, and Manufacturing

• Presented by Dr. Kelly Kroeger, Science & Technology Advisor, Agilent Technologies

With immunology and immune-based therapies rising as a pillar of science and therapeutics, we are seeing a foundational shift from targeting specific proteins and pathways to actually targeting the immune cellular network that resolves and prevents disease. Therefore there is a critical need for cell analysis tools to facilitate understanding of the dynamic nature of the interaction of these cellular networks whether it is in the context of immune cells or immune cells with cancer cells.

To address these new challenges, we at Agilent Technologies have developed a portfolio of cell analysis solutions that provide researchers with more relevant tools to measure living cells, dynamically track them, and model their microenvironments. These next-generation therapies require methods and technologies to enable assessment of real-time cell function, phenotype, and fate. Used together, the Agilent tool bench provides the capability to measure and develop immune cell function more effectively, thus enabling translational researchers and developers to achieve the necessary level of potential therapeutic potency and safety.